- Home
- CTLP vs MYGN Comparison
CTLP vs MYGN Comparison
Compare CTLP & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTLP
- MYGN
- Stock Information
- Founded
- CTLP 1992
- MYGN 1991
- Country
- CTLP United States
- MYGN United States
- Employees
- CTLP N/A
- MYGN N/A
- Industry
- CTLP EDP Services
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CTLP Technology
- MYGN Health Care
- Exchange
- CTLP Nasdaq
- MYGN Nasdaq
- Market Cap
- CTLP 807.9M
- MYGN 744.7M
- IPO Year
- CTLP N/A
- MYGN 1995
- Fundamental
- Price
- CTLP $11.11
- MYGN $4.51
- Analyst Decision
- CTLP Hold
- MYGN Hold
- Analyst Count
- CTLP 5
- MYGN 15
- Target Price
- CTLP $11.50
- MYGN $15.14
- AVG Volume (30 Days)
- CTLP 1.7M
- MYGN 1.3M
- Earning Date
- CTLP 09-09-2025
- MYGN 08-05-2025
- Dividend Yield
- CTLP N/A
- MYGN N/A
- EPS Growth
- CTLP 404.65
- MYGN N/A
- EPS
- CTLP 0.80
- MYGN N/A
- Revenue
- CTLP $292,642,000.00
- MYGN $831,300,000.00
- Revenue This Year
- CTLP $15.44
- MYGN N/A
- Revenue Next Year
- CTLP $15.82
- MYGN $6.68
- P/E Ratio
- CTLP $13.89
- MYGN N/A
- Revenue Growth
- CTLP 12.51
- MYGN 7.38
- 52 Week Low
- CTLP $5.82
- MYGN $3.81
- 52 Week High
- CTLP $11.36
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- CTLP 74.68
- MYGN 40.01
- Support Level
- CTLP $11.02
- MYGN $4.97
- Resistance Level
- CTLP $11.16
- MYGN $5.37
- Average True Range (ATR)
- CTLP 0.04
- MYGN 0.28
- MACD
- CTLP -0.09
- MYGN -0.07
- Stochastic Oscillator
- CTLP 72.22
- MYGN 2.34
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.